View Older Stories View More Recent Stories
-
Jazz Pharmaceuticals (JAZZ) PT Raised at RBC Capital on 'Meaningful Upside' Potential
-
Stifel Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
-
Jazz Pharmaceuticals licenses epilepsy drug from Saniona for $42.5M
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $225 at BofA Securities
-
FDA approves Jazz Pharmaceuticals' dordaviprone for rare brain cancer
-
Jazz Pharmaceuticals (JAZZ) Misses Q2 EPS by 63c
-
Deutsche Bank Starts Jazz Pharmaceuticals (JAZZ) at Buy
-
Jazz Pharmaceuticals names Renee Gala as CEO, Bruce Cozadd to retire
-
Jazz Pharmaceuticals (JAZZ) Receives EU Marketing Authorization for Ziihera
-
Stifel Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
-
Jazz Pharmaceuticals (JAZZ) Reports Zepzelca and Atezolizumab Combination Granted FDA Priority Review
-
Jazz Pharmaceuticals (JAZZ) presents phase 4 Xywav data
-
UBS Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
-
Jazz Pharmaceuticals (JAZZ) Announces Zepzelca and Atezolizumab Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
-
Jazz Pharmaceuticals (JAZZ) Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera in mGEA
-
Biotech stocks Q1 earnings review
-
Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 313c; offers guidance
-
TD Cowen Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
-
Jazz Pharmaceuticals (JAZZ) Completes Acquisition of Chimerix
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
BofA on Jazz Pharmaceuticals (JAZZ): 'sell-off looks overblown'
-
Jazz Pharmaceuticals (JAZZ) PT Lowered to $166 at UBS
-
Cantor Biotech industry report, buying value in RevGens
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $217 at H.C. Wainwright
-
UBS Upgrades Jazz Pharmaceuticals (JAZZ) to Buy
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $230 at Truist Following Chimerix Acquisition
-
JAZZ (JAZZ) to Acquire Chimerix (CMRX) for $8.55/sh Cash
-
Jazz Pharmaceuticals (JAZZ) PT Lowered at RBC as 'Lighter Pipeline Puts Commercial Execution in Spotlight'
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $210 at Needham
-
Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 81c, provides guidance
-
Jazz Pharmaceuticals Joins the Movement for Awareness and Support on World Cancer Day with The Upside Down Challenge
-
TD Cowen: '10 Potential "Thome Run" Catalysts to Watch in 2025'
-
TD Cowen Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ) Following CEO Transition Plan Announcement
-
Jazz Pharmaceuticals (JAZZ) Announces CEO Change
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $220 at Truist Securities
-
Morgan Stanley Upgrades Jazz Pharmaceuticals (JAZZ) to Overweight
-
Piper Sandler Reiterates Overweight Rating on Jazz Pharmaceuticals (JAZZ); Awaiting GEA Data for Ziihera
-
Piper Sandler Provides 'Expert Perspectives On Orexin Agonists And An Evolving Sleep/Wake Space'
-
Jazz Pharmaceuticals (JAZZ) Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $160 at Jefferies
-
TD Cowen Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
-
Jazz Pharmaceuticals (JAZZ) PT Lowered to $163 at Piper Sandler
-
Jazz Pharmaceuticals (JAZZ) Announces FDA Approval of Ziiher
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $162 at Baird
-
Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by $1.11, Beats on Revenue; Offers FY24 Guidance
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $179 at RBC Capital
-
Jazz Pharmaceuticals (JAZZ) Reports Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca and Atezolizumab Combination
-
Jazz Pharmaceuticals (JAZZ) Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO
-
Stifel Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
-
Jazz Pharmaceuticals (JAZZ) Prices $850M Notes Offering
